Deal Announcements

Celladon Closes $43 Million VC Investment

Friday, February 17, 2012 5:54:00 AM PDT | VentureDeal Staff

   La Jolla, California  --  Biotechnology company Celladon has secured $43 million in new venture capital and strategic investment.

Celladon is developing treatments for cardiovascular diseases through advances in molecular cardiology.

Pfizer Venture Investments led the round, which included the Novartis Venture Fund, Hambrecht & Quist Capital Management, GBS Venture Partners, Enterprise Partners Venture Capital, Johnson & Johnson Development Corporation and Venrock.

The company said it would use the financing to advance its lead investigational product candidate for the treatment of advanced heart failure.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1